GRACEcast Radiation Oncology Video
Activity Overview
Episode publication activity over the past year
Episodes
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
02 May 2013
Contributed by Lukas
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on, and the particular markers they ...
Dr. Larry Einhorn: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
01 May 2013
Contributed by Lukas
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, gives his view on more widespread availability of ne...
Dr. Ravi Salgia on the CollabRx System for Matching Patients with Mutations to Clinical Trials
01 May 2013
Contributed by Lukas
Dr. Ravi Salgia, University of Chicago, describes the CollabRx system, which matches patients with particular mutations to appropriate clinical trials...
Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
01 May 2013
Contributed by Lukas
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lun...
Dr. Karen Kelly: Do You Continue a Treatment Beyond 4-6 Cycles to Exhaust its Benefit?
01 May 2013
Contributed by Lukas
Dr. Karen Kelly, of the University of California, Davis, provides her thoughts on whether to continue an effective treatment beyond 4-6 cycles in an e...
Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
27 Apr 2013
Contributed by Lukas
David Spigel, Sarah Cannon Cancer Center, reviews how he discusses the potential advantages and disadvantages waiting on molecular marker results and ...
Dr. Sarah Goldberg: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
27 Apr 2013
Contributed by Lukas
Dr. Sarah Goldberg, from Yale Cancer Center, offers her insights on how to approach a patient with gradual progression in a single site, especially in...
Dr. Lecia Sequist on Multiplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
27 Apr 2013
Contributed by Lukas
Dr. Lecia Sequist of Massachusetts General Hospital, discusses the concept of multiplex next generation sequencing and how it could change molecular o...
Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
27 Apr 2013
Contributed by Lukas
Dr. Rosalyn Juergens, McMaster University, addresses the question of whether to obtain molecular marker results in patients with early stage lung canc...
Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
26 Apr 2013
Contributed by Lukas
Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression f...
Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
24 Apr 2013
Contributed by Lukas
Drs. Ross Camidge and Corey Langer give their views on more widespread availability of new mutation tests.
Dr. Sumanta (Monty) Pal on the Role of Chemotherapy in the Treatment of Kidney Cancer
24 Apr 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal reviews the current role of chemotherapy in the treatment of kidney cancer.
Dr. Phil Bonomi, Rush University: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
18 Apr 2013
Contributed by Lukas
Dr. Phil Bonomi, from Rush University, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will becom...
Dr. Karen Kelly on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
18 Apr 2013
Contributed by Lukas
Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful i...
Dr. David Spigel: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
18 Apr 2013
Contributed by Lukas
Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN expresses his practice pattern for patients with advanced non-small cell lung cancer...
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
18 Apr 2013
Contributed by Lukas
Dr. Sarah Goldberg from Yale Cancer Center describes the methods she uses to obtain tissue samples for molecular testing.
Dr. Lecia Sequist: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
18 Apr 2013
Contributed by Lukas
Dr. Lecia Sequist of Massachusetts General Hospital offers her insights on how to approach a patient with gradual progression in a single site, especi...
Managing Pancreatic Cancer: Surgery for Pancreatic Cancer, Its Complications, and the Importance of Surgical Volume (video)
17 Apr 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the ...
Managing Pancreatic Cancer: Surgery for Pancreatic Cancer, Its Complications, and the Importance of Surgical Volume (audio)
17 Apr 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, covers what surgery for pancreatic cancer entails, what the recovery process is like, and the ...
Dr. Rosalyn Juergens on "I Just Found Out I Have an EGFR Mutation, and I'm in the Middle of Chemo. What Now?"
12 Apr 2013
Contributed by Lukas
Dr. Rosalyn Juergens, McMaster University, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutati...
Dr. Larry Einhorn on "What Have Been the Most Significant Changes in Cancer Care over the Past Decade or Two?"
12 Apr 2013
Contributed by Lukas
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, on what he sees as the most significant changes in c...
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
12 Apr 2013
Contributed by Lukas
Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular marke...
Dr. Geoffrey Oxnard: Are Patients or Payers Objecting to Repeat Biopsy?
12 Apr 2013
Contributed by Lukas
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.
Dr. Greg Riely on Muliplex Next Generation Sequencing and its Effect on Molecular Oncology Practice
11 Apr 2013
Contributed by Lukas
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncolog...
Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
11 Apr 2013
Contributed by Lukas
Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer ove...
Dr. Karen Kelly on "My Approach to Maintenance Therapy for Advanced NSCLC"
10 Apr 2013
Contributed by Lukas
Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance...
Dr. David Spigel on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
10 Apr 2013
Contributed by Lukas
Dr. David Spigel addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with tha...
Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (video)
09 Apr 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and th...
Dr. Matthew Katz: Defining Resectability of Pancreatic Cancer (audio)
09 Apr 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, discusses the factors that determine whether a person's pancreatic cancer is resectable and th...
Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
08 Apr 2013
Contributed by Lukas
Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for pati...
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
08 Apr 2013
Contributed by Lukas
Drs. Ross Camidge and Corey Langer provide their perspective on the likelihood that molecular oncology principles and targeted therapies will become m...
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)
07 Apr 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for ...
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)
07 Apr 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, summarizes evidence from the PARAMOUNT trial, demonstrating a survival benefit for ...
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
05 Apr 2013
Contributed by Lukas
Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests
Dr. Heather Wakelee: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
05 Apr 2013
Contributed by Lukas
Dr. Heather Wakelee from Stanford University offers her insights on how to approach a patient with gradual progression in a single site, especially in...
Dr. Ravi Salgia: How Do I Discuss the Side Effects of Targeted Therapies, as Compared with Chemotherapy?
03 Apr 2013
Contributed by Lukas
Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for ...
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
03 Apr 2013
Contributed by Lukas
Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, an...
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
31 Mar 2013
Contributed by Lukas
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a...
Dr. Geoffrey Oxnard on What Molecular Markers to Test for in Advanced NSCLC, and in Whom?
31 Mar 2013
Contributed by Lukas
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular test...
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
30 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 imm...
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (audio)
30 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes new targets for squamous cell non-small cell lung cancer and anti-PD1 imm...
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (video)
29 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor ...
Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)
29 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor ...
Dr. Matthew Katz: Staging Pancreatic Cancer (video)
29 Mar 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic canc...
Dr. Matthew Katz: Staging Pancreatic Cancer (audio)
29 Mar 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, reviews the general concept of cancer staging, the basic workup and staging of pancreatic canc...
Dr. Matthew Katz: Introduction to Pancreatic Cancer (video)
29 Mar 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a descrip...
Dr. Matthew Katz: Introduction to Pancreatic Cancer (audio)
29 Mar 2013
Contributed by Lukas
Dr. Matthew Katz, surgeon at MD Anderson Cancer Center, provides a general introduction to the form and function of the pancreas, along with a descrip...
Dr. Sarah Goldberg on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer
29 Mar 2013
Contributed by Lukas
Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with t...
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
29 Mar 2013
Contributed by Lukas
Dr. Lecia Sequist of Massachusetts General Hospital describes the new targets she envisions as relevant for effective treatments in lung cancer over t...
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years
25 Mar 2013
Contributed by Lukas
Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer...
Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
25 Mar 2013
Contributed by Lukas
Drs. Ross Camidge and Corey Langer offer their insights on how to approach a patient with gradual progression in a single site, especially in the brai...
What is the Right Surgery for Early Stage Kidney Cancer?, by Dr. Monty Pal
25 Mar 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal reviews the questions on the role of surgery and what type of surgery to pursue for early stage kidney cancer.
Dr. David Spigel: We've Probably Made Maintenance Therapy More Complicated Than It Needs To Be
25 Mar 2013
Contributed by Lukas
Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN, discusses the evidence and his personal interpretation and recommended approach to ...
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (video)
23 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advance...
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)
23 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, describes emerging data on the efficacy of ALK inhibitors for patients with advance...
Dr. Alan Sandler: My Approach to Acquired Resistance for Targeted Therapies in Lung Cancer
21 Mar 2013
Contributed by Lukas
Dr. Alan Sandler from OHSU describes how acquired resistance to targeted therapies in lung cancer is similar to what is seen with chemo and comments o...
Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
21 Mar 2013
Contributed by Lukas
Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer ...
Dr. Ravi Salgia on "My Approach to Maintenance Therapy for Advanced NSCLC"
20 Mar 2013
Contributed by Lukas
Dr. Ravi Salgia from University of Chicago provides his general strategy for patients with advanced non-small cell lung cancer who are candidates for ...
Dr. William Pao on "How Concerned Should We Be About Different Testing Methods, as well as the Heterogeneity of Different Biopsy Results from the Same Patient?"
20 Mar 2013
Contributed by Lukas
Dr. William Pao explains the caveats of molecular testing in terms of differences in testing methods through different laboratories and the heterogene...
Dr. Monty Pal on Leading Options for First Line Treatment of Advanced Kidney Cancer
19 Mar 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal, medical oncologist at City of Hope Cancer Center in Duarte, CA, explains the range of options and his approach to first line ...
Dr. Larry Einhorn: What are the Biggest Challenges We Face in Delivering Effective Cancer Care in the Next Decade?
19 Mar 2013
Contributed by Lukas
Dr. Larry Einhorn, Distinguished Professor of Medicine at Indiana Univ and former ASCO president, discusses leading challenges he sees for effective d...
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (video)
18 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patien...
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
18 Mar 2013
Contributed by Lukas
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patien...
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
14 Mar 2013
Contributed by Lukas
Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a c...
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
14 Mar 2013
Contributed by Lukas
Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a rep...
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
13 Mar 2013
Contributed by Lukas
Dr. Karen Reckamp, City of Hope Cancer Center, provides her perspective on the likelihood that molecular oncology principles and targeted therapies wi...
Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC
13 Mar 2013
Contributed by Lukas
Dr. Rosalyn Juergens, McMaster University, explains her approach to management of acquired resistance to targeted therapies in patients with a "driver...
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (video)
12 Mar 2013
Contributed by Lukas
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robo...
Dr. Harpole on Lung Surgery (Part 2): Advances in Surgical Techniques (audio)
12 Mar 2013
Contributed by Lukas
Dr. David Harpole of Duke University reviews advances in lung cancer surgery, covering techniques ranging from video-assisted thoracic surgery to robo...
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
11 Mar 2013
Contributed by Lukas
Dr. Alan Sandler, Oregon Health and Science University, considers the various options for maintenance therapy as well as a potential treatment break a...
Dr. Pal on the Role of Interleukin-2 (IL-2) in Advanced Kidney Cancer Today
11 Mar 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center discusses the current role of interleukin-2 (IL-2) in the context of many other treatment altern...
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
11 Mar 2013
Contributed by Lukas
Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and...
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?
10 Mar 2013
Contributed by Lukas
Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which pati...
Dr. Monty Pal: Reviewing Bladder Cancer Stages, the Role of Surgery, and the Potential Role of Chemotherapy for Localized Bladder Cancer
07 Mar 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal, City of Hope Cancer Center, summarizes basic stages of bladder cancer, value of surgery, and survival benefit of neoadjuvant ...
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
07 Mar 2013
Contributed by Lukas
Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients n...
Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?
07 Mar 2013
Contributed by Lukas
Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung ...
Dr. David Spigel: Which Lung Cancer Patients Should We Be Doing Molecular Marker Testing For, and Should We Do "Reflex Testing"?
07 Mar 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing...
Dr. Larry Einhorn: Will Costs of Care Limit Our Ability to Deliver Cancer Treatments?
05 Mar 2013
Contributed by Lukas
Dr. Larry Einhorn, Indiana University, expresses his concerns about the cost of developing cancer drugs and the challenge of paying for extremely expe...
Dr. Larry Einhorn: How Can We Replicate the High Cure Rates We've Achieved for Testicular Cancer in a Wide Range of Cancers?
05 Mar 2013
Contributed by Lukas
Dr. Larry Einhorn, Indiana University, explains why some cancers such as testicular cancer can have such a high cure rate while most others are far mo...
Dr. Monty Pal on the Current Best Practices for Early Stage Kidney Cancer
05 Mar 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA describes optimal management of kidney cancer that is confined to the kidney, incl...
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
04 Mar 2013
Contributed by Lukas
Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung c...
Dr. Greg Riely: How I Use Molecular Marker Information in Earlier Stage NSCLC Patients
04 Mar 2013
Contributed by Lukas
Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially b...
Dr. Geoffrey Oxnard on Managing Acquired Resistance to EGFR Inhibitor Therapy (and Probably Crizotinib, Too)
04 Mar 2013
Contributed by Lukas
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing patients with advanced NSCLC who experience acq...
Dr. Karen Reckamp: Recommending a Repeat Biopsy, at Initial Diagnosis or with Acquired Resistance to a Targeted Therapy
03 Mar 2013
Contributed by Lukas
Dr. Karen Reckamp, City of Hope Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression f...
Dr. WIlliam Pao on the Goals for Developing MyCancerGenome.org
01 Mar 2013
Contributed by Lukas
Dr. William Pao describes how the developers of MyCancerGenome.org envision the website resource being used to help cancer patients, both now and in t...
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?
01 Mar 2013
Contributed by Lukas
Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therap...
Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse
01 Mar 2013
Contributed by Lukas
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both i...
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
28 Feb 2013
Contributed by Lukas
Dr. Alan Sandler, Oregon Health and Science University, describes how he sees very specialized molecular testing for lung cancer becoming increasingly...
Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?
28 Feb 2013
Contributed by Lukas
Dr. Phil Bonomi provides his views on the value of maintenance therapy for advanced non-small cell lung cancer and the various alternatives among main...
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?
27 Feb 2013
Contributed by Lukas
Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of...
Dr. Monty Pal: How Do We Work Up a Kidney Mass That May Be Cancer?
27 Feb 2013
Contributed by Lukas
Dr. Sumanta (Monty) Pal of City of Hope Cancer Center in Duarte, CA reviews a recommended approach to the workup of a kidney mass suspected to be a ca...
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn't Enough Tissue for Molecular Testing?
25 Feb 2013
Contributed by Lukas
Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue...
Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
25 Feb 2013
Contributed by Lukas
Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking addi...
Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
25 Feb 2013
Contributed by Lukas
Dr. Karen Kelly describes her thought process on which molecular markers are those clearly indicated for testing in patients with advanced NSCLC, as w...
Dr. Heather Wakelee: Do You Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?
25 Feb 2013
Contributed by Lukas
Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have tes...
Dr. Greg Riely: How Should We Approach Acquired Resistance to Targeted Therapies in Advanced NSCLC?
23 Feb 2013
Contributed by Lukas
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in ad...
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
23 Feb 2013
Contributed by Lukas
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer o...
Dr. Lecia Sequist on Molecular Marker Testing in Advanced NSCLC in 2013: What, Who, and When?
22 Feb 2013
Contributed by Lukas
Dr. Lecia Sequist describes the state of the art and her view of current best practices on molecular testing for advanced non-small cell lung cancer.
What is an Inherited T790M EGFR Mutation, and What Does It Mean?
22 Feb 2013
Contributed by Lukas
Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a ...
What is MyCancerGenome.org?
22 Feb 2013
Contributed by Lukas
Dr. William Pao describes the MyCancerGenome.org website and how data on a wide range of mutations is incorporated to build this database to help phys...